Actualités et vidéos - SPINEWAY

Press release Ecully, April 16, 2024 – 8 p.m. First-quarter 2024 revenue of €3.1 million Growth of 28% compared with 2023 first quarter In thousands of euros 2024 2023 Change 2023/2022 Q1 revenue 3,070 2,398 +28% Unaudited consolidated data Spineway, a specialist in innovative implants for the treatment of severe spine disorders, recorded revenue of €3.1 million in the first quarter of 2024, an increase of 28% compared with the same period in 2023. This purely organic growth (with no scope...

Communiqué de presse Ecully, le 26 mars 2024 – 20h Compte-rendu de l’Assemblée Générale du 25 mars 2024 L'Assemblée Générale Mixte (Ordinaire et Extraordinaire) des actionnaires de Spineway s'est tenue sur première convocation ce lundi 25 mars 2024 à 16h au siège social de la société, 7 allée Moulin Berger à Ecully (69). Compte tenu de la représentation des actionnaires défaillants par le SELARL TULIER POLGE ALIREZAI, en qualité de mandataire ad hoc nommé par Ordonnance du...

Press release Ecully, February 29, 2024 – 6:00 p.m. Effective date of the Spineway reverse stock split Spineway announces the completion of the reverse stock split by exchanging 1 new share of 4.00 euros par value for 2,000 old shares of 0.002 euro par value. This transaction, which was carried out pursuant to a decision by the Company's shareholders at an Extraordinary General Meeting held on November 10, 2023, took effect on February 27, 2024. The old Spineway shares with a par value of...

Combined General Meeting of March 25, 2024 Availability of preparatory documents Spineway informs its shareholders that they are invited to attend the Combined General Meeting to be held on Monday, March 25, 2024 at 16:00 p.m . at the Group's headquarters, 7 allée Moulin Berger in Ecully (69). The notice of meeting, which is valid as a notice of convocation, including the agenda and the text of the resolutions presented to the General Meeting, was published in the Bulletin des Annonces Légales...

Press release Ecully, February 7, 2024 – 6 p.m. SPINEWAY 2023 annual results 2023 revenue of €10.5 million (+42%) Gross margin steady at 69% Net income heavily impacted by exceptional items Implementation in 2024 of a streamlining plan to achieve operating breakeven in the medium term 1 In thousands of euros Consolidated accounts 2023 2022 Revenue 10,519 7,432 Cost of sales (3,309) (2,320) Gross margin 7,210 5,112 % of revenue 69% 69% Net operating expenses (11,727) (8,322) Of which running...

Press release Ecully, January 25, 2024 – 6.00 p.m. 2023 revenue of €10.5 million In thousands of euros Unaudited data 2023 2022 % change Q1 revenue 2,399 1,342 +79% Q2 revenue 3,034 1,770 +71% Q3 revenue 2,077 2,249 -8% Q4 revenue 3,009 2,071 +45% Full-year revenue 10,519 7,432* +42% * 2022 revenue includes the share of revenue derived from Spine Innovations since its consolidation on July 21, 2022, i.e. €1.7 million. Spineway recorded revenue of €10.5 million in 2023, an increase of 42%...

Press release Ecully, January 5, 2024 – 6.00 pm Reverse split of Spineway shares Reverse split by exchange of 2,000 existing shares for 1 new share Start of share split period: January 25, 2024 Effective date of share split: February 27, 2024 Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that it has decided to carry out a reverse split of its share capital on the basis of 1 new share for 2,000 old shares. Implementation of the share split...

Communiqué de presse Ecully, le 5 janvier 2024 – 18h00 Lancement d’un regroupement d’actions Spineway Regroupement par voie d’échange de 2 000 actions existantes contre 1 action nouvelle Début de l’opération de regroupement : 25 janvier 2024 Prise d’effet du regroupement : 27 février 2024 Spineway spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce avoir décidé de mettre en œuvre un regroupement des...

Press release Ecully, November 24, 2023 – 8.45 a.m. SPINEWAY International rollout of the VEOS implant range First implants in Spain New approvals in Colombia and Indonesia The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces the accelerated rollout of its range of VEOS implants for intervertebral fixation by posterior approach into new markets. This technology, which addresses the largest segment of the spine implant market, estimated...

Press release Ecully, November 13, 2023 – 6.00 p.m. Minutes of the General Meeting of November 10, 2023 An Extraordinary General Meeting of Spineway shareholders was held on first notice on Friday, November 10, 2023 at 9:30 a.m. at the company’s registered office, 7 allée Moulin Berger in Ecully (69). Taking into account the representation of defaulting shareholders by SELARL TULIER POLGE ALIREZAI, as ad hoc agent appointed by Order of the President of the Commercial Court of Lyon dated...

Press release Ecully, November 7, 2023 – 6.00 p.m. Appointment of Sandrine Carle as Deputy Chief Executive Officer The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces the appointment of Sandrine Carle as Deputy Chief Executive Officer. Ms. Carle joined Spineway in July 2022, at the time of the acquisition of Spine Innovations, where she was CEO. She was instrumental in the successful integration of Spine Innovations into the Spineway...

Press release Ecully, Novembre 2, 2023 – 6:30 p.m. VEOS system well perceived at the NASS 2023 conference in the United States Sales growth in France Spineway Group, specialists in innovative implants for the treatment of severe spinal pathologies, is pleased to announce that its VEOS posterior spinal fixation system received an excellent response from the spine implant industry at the North American Spine Society (NASS) Congress in Los Angeles last October 1 . During the event, the Group...

Press release Ecully, October 19, 2023 – 6 p.m. Spineway obtains 510(k) clearance from the FDA for its VEOS spinal fixation system Spineway Group, a specialist in innovative implants for the treatment of severe spinal conditions, is pleased to announce the recent 510(k) clearance from the US Food and Drug Administration (FDA) for its VEOS Spinal Fixation System. This clearance, which allows Spineway Group to market its VEOS system in the US, represents a significant achievement for the Group...

Communiqué de presse Ecully, le 13 octobre 2023 – 18h Chiffre d’affaires 9 mois de 7,5 M€ en hausse de 40% En milliers d’euros Chiffres non audités 2023 2022 Variation 2023/2022 CA 1 er trimestre 2 399 1 342 + 79% CA 2 e trimestre 3 034 1 770 + 71% CA 3 e trimestre 2 077 2 249 - 8% CA 9 mois * 7 509 5 361 + 40% * Le chiffre d’affaires à fin septembre 2022 inclut la quote-part de chiffre d’affaires lié à Spine Innovations depuis son intégration le 21 juillet 2022, soit 0,9 M€....

C ommuniqué de presse Ecully , le 19 septembre 202 3 – 18 h Résultats semestriels 202 3 Croissance du chiffre d’affaires sur le 1 er semestre (+ 75%) Marge brute de 3,9 M€ (72% du CA) Poursuite des investissements Nouveaux financements pour accompagner les développements En milliers d'euros Comptes consolidés S1 202 3 S1 202 2 Chiffre d'affaires 5 432 3 113 Coût des ventes - 1 509 - 1 036 Marge brute * % du CA 3 923 72 % 2 077 67 % Coûts nets d’exploitation Dont coûts de...

Spineway organizes an international masterclass with expert spine surgeons Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that its Spineway Academy department, with the support of GECO 1 (Groupe d’études de la Chirurgie Osseuse – Bone Surgery Study Group) and its SAC (Spine Arthroplasty Community) working group, has organized a masterclass on cervical and lumbar disc prostheses with French and international surgeons. This event was held...

Communiqué de presse Ecully , le 1 1 juillet 202 3 – 1 8 h SPINEWAY Ch iffre d’affaires du 1 er semestre 2023 de 5,4 M€ (+ 75 %) Poursuite de la montée en puissance des produits Distimp Forte progression des ventes en Europe En milliers d’euros Chiffres non audités 2023 2022 Variation 202 3 /202 2 en % CA 1 er trimestre 2 399 1 342 + 79 % CA 2 e trimestre 3 033 1 770 + 71% CA 1 er semestre 5 432 3 113 + 75% Spineway totalise sur le 1 er semestre 2023 un chiffre d’affaires de 5,4 M...

Press release Ecully , May 25 , 2023 – 8 a.m. Strengthening of the cash position in support of the Group’s developments “Without compromising on its values, purpose or strategy, the Spineway Group has achieved a genuine transformation of its organization and product offering, which is starting to pay off. Our aim of becoming a benchmark in less invasive spine surgery more than ever requires a strengthening of our range of premium products and services. To that end, we must maintain a...

Communiqué de presse Ecully , le 13 avril 202 3 – 1 8 h Ch iffre d’affaires du 1 er trimestre 2023 de 2,4 M€ (+ 7 9 %) En milliers d’euros 2023 2022 Variation en % CA 1 er trimestre 2 399 1 342 + 7 9 % Données consolidées non auditées Spineway totalise sur le 1 er trimestre 2023 un chiffre d’affaires de 2,4 M €, dont la croissance de 7 9 % par rapport au T1 2022 est principalement liée aux ventes de s prothèses discales de Spine Innovations . Retraité es de cette contribution,...

Press release Ecully , April 13, 2023 – 6 p.m. First-quarter 2023 revenue of €2.4 million (+7 9 %) In thousands of euros 2023 2022 Change as a % Q1 revenue 2,399 1,342 +7 9 % Unaudited consolidated data Spineway has achieved a total revenue of €2.4 million as of Q1 2023, representing growth of 7 9 % compared with Q1 2022, mainly driven by sales of Spine Innovations’ disc prostheses. Adjusted for this contribution, quarterly revenue remain s robust and represent s an all-time high of...